Research programme: glycogen storage disease type I therapeutics - Prime Medicine
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Prime Medicine
- Class Gene therapies
- Mechanism of Action SLC37A4 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glycogen storage disease type I